Coya Therapeutics (NASDAQ:COYA – Get Free Report) is one of 942 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Coya Therapeutics to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends.
Institutional & Insider Ownership
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 9.8% of Coya Therapeutics shares are owned by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Coya Therapeutics and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Coya Therapeutics | N/A | -42.53% | -37.57% |
Coya Therapeutics Competitors | -2,796.54% | -231.74% | -28.98% |
Valuation & Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
Coya Therapeutics | $6.00 million | -$7.99 million | -11.72 |
Coya Therapeutics Competitors | $8.67 billion | $128.65 million | -4.72 |
Coya Therapeutics’ rivals have higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings and price targets for Coya Therapeutics and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Coya Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Coya Therapeutics Competitors | 5820 | 17154 | 40849 | 818 | 2.57 |
Coya Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 53.17%. As a group, “Pharmaceutical preparations” companies have a potential upside of 69.65%. Given Coya Therapeutics’ rivals higher possible upside, analysts clearly believe Coya Therapeutics has less favorable growth aspects than its rivals.
Volatility & Risk
Coya Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Coya Therapeutics’ rivals have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.
Summary
Coya Therapeutics rivals beat Coya Therapeutics on 9 of the 13 factors compared.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.